Shares of Biogen, a US biotech company, trade around 50% higher in premarket today. Shares rally following results of an Alzheimer drug (Lecanemab) trial that Biogen developed along with Eisai, Japanese pharmaceutical company. Results showed that the pace of cognitive decline in patients who received Lecanemab dropped by 27% over 18 months compared to patients who received placebo. This is massive as it is the first drug to show effectiveness against Alzheimer in a definitive, large-scale trial. While the company noted that some side effects occurred, it also said that they were rarely severe.
Biogen trades around 50% higher in premarket today. Weekly chart. Source: xStation5
Gaming companies with huge discounts 🚨 Will Project Genie end the traditional era of gaming ❓
Lockheed Martin earnings: The peak of global tensions and valuations
Market wrap: European indices outperform US stocks ahead of the opening bell on Wall Street 📉
Apple’s Record Quarter: iPhone, Services, and ‘Invisible’ AI. Is a Return to the Throne Imminent?